Log in to save to my catalogue

Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deteri...

Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deteri...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_3072932090

Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial

About this item

Full title

Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial

Publisher

United States: Public Library of Science

Journal title

PloS one, 2023, Vol.18 (12), p.e0295838

Language

English

Formats

Publication information

Publisher

United States: Public Library of Science

More information

Scope and Contents

Contents

Anakinra and tocilizumab are used for severe Covid-19, but only one previous randomized controlled trial (RCT) has studied both. We performed a multi-center RCT comparing anakinra or tocilizumab versus usual care (UC) for adults at high risk of deterioration.
The study was conducted June 2020 to March 2021. Eligibility required ≥ 5 liters/minute...

Alternative Titles

Full title

Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_plos_journals_3072932090

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_3072932090

Other Identifiers

ISSN

1932-6203

E-ISSN

1932-6203

DOI

10.1371/journal.pone.0295838